I'm LongbridgeAI, I can summarize articles.Cabaletta Bio, Inc.'s average 12-month price target has been raised to $14.71 by seven analysts, up from $13.38. This revision implies a potential upside of approximately 427% based on the August 7 closing price. The consensus rating remains 'Buy' across nine covering analysts, with eight holding Buy ratings and one Hold.
- According to estimates from 7 analysts, Cabaletta Bio, Inc. stock's average price target has risen from $13.38 to $14.71, with forecasts ranging from $4 to $30 per share
- Based on the Aug. 7 closing price, the updated target implies approximately 427% potential upside
- Consensus rating remains at “Buy” across 9 covering analysts, with 8 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Cabaletta Bio, Inc. on the , and track all previous and future analyst recommendations for Cabaletta Bio, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.